Evolent Health
About: Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Employees: 4,500
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
229% more call options, than puts
Call options by funds: $5.46M | Put options by funds: $1.66M
50% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]
13% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 72
2.23% more ownership
Funds ownership: 105.03% [Q4 2024] → 107.26% (+2.23%) [Q1 2025]
7% less funds holding
Funds holding: 239 [Q4 2024] → 223 (-16) [Q1 2025]
14% less capital invested
Capital invested by funds: $1.38B [Q4 2024] → $1.18B (-$191M) [Q1 2025]
24% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 54
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$13
38%
upside
Avg. target
$14.75
57%
upside
High target
$16
70%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Truist Securities Jailendra Singh | 70%upside $16 | Buy Maintained | 17 Jul 2025 |
JMP Securities Constantine Davides | 38%upside $13 | Market Outperform Reiterated | 20 Jun 2025 |
Needham Ryan MacDonald | 59%upside $15 | Buy Reiterated | 13 May 2025 |
UBS Kevin Caliendo | 59%upside $15 | Buy Maintained | 9 May 2025 |
Financial journalist opinion
Neutral
PRNewsWire
2 weeks ago
Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Company to Participate in Upcoming Conferences WASHINGTON , July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Neutral
PRNewsWire
2 weeks ago
Evolent announces key appointments to leadership team
Dr. David Lim joins Evolent as chief clinical officer John Way joins Evolent as CFO, Performance Suite WASHINGTON , July 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced leadership additions to its clinical and financial teams, as it continues to drive innovation in specialty care. Physician, executive and startup entrepreneur Dr. David Lim has joined the company as chief clinical officer, where he will lead Evolent's 300-person medical team to support daily operations and innovation.
Positive
Zacks Investment Research
1 month ago
Evolent Health (EVH) Stock Jumps 6.9%: Will It Continue to Soar?
Evolent Health (EVH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
PRNewsWire
1 month ago
Evolent reiterates Q2 and full year guidance for Adjusted EBITDA
Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON , June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-165M.
Neutral
Seeking Alpha
2 months ago
Evolent Health, Inc. (EVH) Q1 2025 Earnings Call Transcript
Evolent Health, Inc. (NYSE:EVH ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Jack Doney - UBS Matthew Gillmor - KeyBanc Ryan Daniels - William Blair Jessica Tassan - Piper Sandler Jeff Garro - Stephens Kyle Aikman - JPMorgan Matthew Shea - Needham Constantine Davides - Citizens Charles Rhyee - TD Cowen Daniel Grosslight - Citi David Larsen - BTIG Operator Welcome to the Evolent Earning Conference Call for the First Quarter Ended March 31, 2025. As a reminder, this conference call is being recorded.
Positive
Zacks Investment Research
2 months ago
Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Evolent Health (EVH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Negative
Zacks Investment Research
2 months ago
Evolent Health (EVH) Q1 Earnings Lag Estimates
Evolent Health (EVH) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.34 per share a year ago.
Neutral
PRNewsWire
2 months ago
Evolent Announces First Quarter 2025 Results
WASHINGTON , May 8, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent Health kicked off 2025 with first quarter results at the high end of our expectations, and we are reiterating our outlook for full year 2025 revenue and Adjusted EBITDA.
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts Believe Evolent Health (EVH) Could Rally 53.33%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 53.3% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
PRNewsWire
3 months ago
Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors
Former CFO of CVS Health, Aetna and Coventry Health Care brings deep experience driving growth and profitability. Mr. Guertin's nomination represents continuation of Evolent's board refreshment efforts.
Charts implemented using Lightweight Charts™